Brief: Rain Oncology Reports First Quarter 2023 Financial Results And Highlights Recent Progress

Rain Oncology

11/05/2023 21:55

Rain Oncology Inc  RAIN.O :
    * RAIN ONCOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
HIGHLIGHTS RECENT PROGRESS
    * RAIN ONCOLOGY INC - QUARTER-END CASH POSITION OF $110
MILLION
PROVIDES RUNWAY TO COMPLETE ALL ONGOING AND PLANNED CLINICAL
TRIALS OF MILADEMETAN
    * RAIN ONCOLOGY INC - TOPLINE DATA FOR MANTRA TRIAL EXPECTED
THIS
QUARTER
    * RAIN ONCOLOGY INC - PHASE 1/2 MANTRA-4 TRIAL IN ADVANCED
SOLID
TUMORS EXHIBITING LOSS OF CDKN2A GENE ON TRACK TO COMMENCE IN
MID-2023
    * RAIN ONCOLOGY INC - QTRLY LOSS PER SHARE $0.56
    * RAIN ONCOLOGY INC - AS OF MARCH 31, 2023, CO HAD $109.8
MILLION
IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
    * RAIN ONCOLOGY INC - CONSISTENT WITH PRIOR QUARTER, CO WILL
NOT
PROVIDE GUIDANCE ON CASH RUNWAY AT THIS TIME
    * RAIN ONCOLOGY - WILL CONTINUE TO ASSESS CASH
RUNWAY,PROVIDE
FURTHER GUIDANCE IN NEXT QUARTER,IF APPROPRIATE,AFTER RELEASE OF
MANTRA TOPLINE RESULTS IN QUARTER

Source text for Eikon:  ID:nGNX5l4cQs 
Further company coverage:  RAIN.O